A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Recruiting

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

Trial locations(64 sites)

China

The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui

Peking University Third Hospital, Beijing, Beijing Municipality

Peking University Peoples Hospital, Beijing, Beijing Municipality

Peking Union Medical College Hospital, Beijing, Beijing Municipality

Chongqing University Three Gorges Central Hospital, Chongqing, Chongqing Municipality